ONCE Overview
Upcoming Projects (ONCE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ONCE)
-
Examining the market size for Hemophilia B gene therapy treatments with a focus on uniQure & Spark
Tickers: QURE, ONCE, PFE
Executed On: Nov 21, 2019 at 02:00 PM EST -
A Second Opinion: Preparing for upcoming 3 year data on BioMarin's gene therapy ValRox in treating patients with hemophilia A
Tickers: BMRN, ONCE, PFE
Executed On: May 17, 2019 at 04:30 PM EDT -
Preparing for upcoming 3 year data on BioMarin's gene therapy ValRox in treating patients with hemophilia A
Tickers: BMRN, ONCE, PFE
Executed On: May 13, 2019 at 12:00 PM EDT -
Another View: Exploring gene therapy treatments in the hemophilia space including those from BioMarin and Spark Therapeutics
Tickers: BMRN, ONCE, PFE
Executed On: Oct 16, 2018 at 05:30 PM EDT -
Exploring gene therapy treatments in the hemophilia space including those from BioMarin and Spark Therapeutics
Tickers: BMRN, ONCE, PFE
Executed On: Oct 15, 2018 at 11:30 AM EDT
Expired Projects (ONCE)
-
Understanding Spark's LUXTURNA potential in RPE65-mediated IRD blindness currently under review at the FDA
Ticker: ONCE
Execute By: Jan 19, 2018
Upcoming & Overdue Catalysts (ONCE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ONCE)
-
Spark's (ONCE) gene therapy SPK-9001 Phase 1/2 in hemophilia B study data released
Ticker: ONCE
Occurred on: May 22, 2018 -
SPK-FIX hemophilia B update expected at ASH 2016
Ticker: ONCE
Occurred on: Dec 04, 2016
Strategic Initiatives (ONCE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
